On November 28, 2018 the Federal law of November 28, 2018 No. 449-FZ “On amendments being made to separate legal acts regarding introduction of drugs into commercial turnover” (the “Law”) was published on the official web portal of legal information.

Lidings, the leading legal advisor in Russia providing legal support to large national and international companies operating in the pharmaceuticals and healthcare sector in Russia and CIS, launces a series of specialized tests on the legislative regulation of the sector.

On October 18, 2018 new wording of the Rules of state registration and re-registration of maximum sale prices established by drug manufacturers for those drugs, that are included in the vital and essential drugs list (“the Rules” and “the Drugs” correspondingly) has been enacted with the amendments introduced by the Russian Government Decree of 08.10.2018 No. 1207 “On amendments to the Russian Government Decree of October, 29 2010 No. 865 and of September, 15 2015 No. 979” (“the Decree”).

Lidings experts have authored the The Pharma Legal Handbook: Russia — practical directory focused on the key aspects of legislative regulation of pharmaceutical industry in Russia.

Partner of the Lidings’ Intellectual Property practice Boris Malakhov will take part in a conference entitled Regulatory Issues in Medical Practice: Regulation and Court Practice organized by Pravo.ru. The event will take part in Moscow, September 19th, 2018 in the Newsroom event hall.

Lidings Managing Partner Andrey Zelenin heading Intellectual Property practice of the firm will conduct a webinar dedicated to the Regulation of Advertisement of Drugs and Overview of Recent Cases as part of a series of webinars led by experts from the leading law firms and heads of legal of large companies, organized by Pravo.ru.

Federal Antimonopoly Service (FAS of Russia) has issued Letter No. АЦ/49132/18 dated 29 June 2018 in which expressed its opinion regarding selling prices for drugs, included in the List of vital and essential drugs (the “Essential drug list”). FAS indicated that these prices, when set by wholesale and retail organizations, shall be dependent on the terms of their purchase.

On 24 April 2018 the Intellectual Property Court published its Decision in case A41 85807/2016 between Swiss-based Novartis AG and local generic Nativa LLC.

At present, the direction of medicine, such as telemedicine, becomes more and more known and the number of questions about the procedure of providing medical assistance using telemedicine is also growing.